
Over the past 10 years the clinical management of urological problems has changed greatly. Whereas in the past nearly 75% of patients referred to a urologist would be treated surgically, now only about 1 patient in 15 requires surgery. This quiet revolution has come about through the introduction of effective drugs over this period, and thus represents a major success for the discipline of pharmacology in providing a basis for the commitment of the pharmaceutical industry. This series of review articles provides an update on developments in this important field and summarises the material presented by invited experts at the third BJP Symposium "The Physiology and Pharmacology of the Lower Urinary Tract". This was a joint symposium organised by the Society for Basic Urology, URODOC and the British Journal of Pharmacology.
The first set of reviews deals with our present understanding of the neuronal pathways involved in controlling urinary storage and expulsion in animals and man, and the ways in which these mechanisms may be disrupted by disease or trauma.
Further articles describe human disease and animal models that mimic different aspects of human pathology, and discuss possible drug targets that may lead to new developments in therapeutics. The final section deals with pharmacological aspects of the treatment of sexual dysfunction, which has become a major therapeutic area.
This series of reviews should provide a critical guide for researchers new to this rapidly developing field, in both academia and industry. We hope that it will stimulate new research suitable for publication in the British Journal of Pharmacology, which has a reputation for excellence in this area.
TABLE OF CONTENTS
Volume 147, Issue S2 (February 2006)
View table of contents by subject categoryIntroduction
The physiology and pharmacology of the lower urinary tract FREE
Br J Pharmacol 147: S1-S1; doi:10.1038/sj.bjp.0706681
Reviews
Review Article
Lower urinary tract disease: what are we trying to treat and in whom? FREE
Jeremy P W Heaton
Br J Pharmacol 147: S2-S13; doi:10.1038/sj.bjp.0706620
Integrated control of lower urinary tract – clinical perspective FREE
Clare J Fowler
Br J Pharmacol 147: S14-S24; doi:10.1038/sj.bjp.0706629
Integrative control of the lower urinary tract: preclinical perspective FREE
William C de Groat
Br J Pharmacol 147: S25-S40; doi:10.1038/sj.bjp.0706604
Molecular mechanisms of detrusor and corporal myocyte contraction: identifying targets for pharmacotherapy of bladder and erectile dysfunction FREE
George J Christ and Steve Hodges
Br J Pharmacol 147: S41-S55; doi:10.1038/sj.bjp.0706627
In vitro models: research in physiology and pharmacology of the lower urinary tract FREE
Robert B Moreland
Br J Pharmacol 147: S56-S61; doi:10.1038/sj.bjp.0706505
Animal models in urological disease and sexual dysfunction FREE
Gordon McMurray, James H Casey and Alasdair M Naylor
Br J Pharmacol 147: S62-S79; doi:10.1038/sj.bjp.0706630
Muscarinic receptors in the bladder: from basic research to therapeutics FREE
Sharath S Hegde
Br J Pharmacol 147: S80-S87; doi:10.1038/sj.bjp.0706560
1-,
2- and
-adrenoceptors in the urinary bladder, urethra and prostate FREE
Martin C Michel and Wim Vrydag
Br J Pharmacol 147: S88-S119; doi:10.1038/sj.bjp.0706619
The role of central 5-hydroxytryptamine (5-HT, serotonin) receptors in the control of micturition FREE
Andrew G Ramage
Br J Pharmacol 147: S120-S131; doi:10.1038/sj.bjp.0706504
Purinoceptors as therapeutic targets for lower urinary tract dysfunction FREE
Anthony P D W Ford, Joel R Gever, Philip A Nunn, Yu Zhong, Joseph S Cefalu, Michael P Dillon and Debra A Cockayne
Br J Pharmacol 147: S132-S143; doi:10.1038/sj.bjp.0706637
Growth factor signalling in prostatic growth: significance in tumour development and therapeutic targeting FREE
Arich Ryan Reynolds and Natasha Kyprianou
Br J Pharmacol 147: S144-S152; doi:10.1038/sj.bjp.0706635


